These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
413 related articles for article (PubMed ID: 36851084)
21. Design of a multi-epitope protein vaccine against herpes simplex virus, human papillomavirus and Chlamydia trachomatis as the main causes of sexually transmitted diseases. Dorosti H; Eskandari S; Zarei M; Nezafat N; Ghasemi Y Infect Genet Evol; 2021 Dec; 96():105136. PubMed ID: 34775078 [TBL] [Abstract][Full Text] [Related]
22. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine. Samandary S; Kridane-Miledi H; Sandoval JS; Choudhury Z; Langa-Vives F; Spencer D; Chentoufi AA; Lemonnier FA; BenMohamed L Hum Immunol; 2014 Aug; 75(8):715-29. PubMed ID: 24798939 [TBL] [Abstract][Full Text] [Related]
24. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients. Le Cleach L; Trinquart L; Do G; Maruani A; Lebrun-Vignes B; Ravaud P; Chosidow O Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD009036. PubMed ID: 25086573 [TBL] [Abstract][Full Text] [Related]
25. Novel agents and strategies to treat herpes simplex virus infections. Kleymann G Expert Opin Investig Drugs; 2003 Feb; 12(2):165-83. PubMed ID: 12556212 [TBL] [Abstract][Full Text] [Related]
26. [Herpes simplex virus vaccine studies: from past to present]. Us D Mikrobiyol Bul; 2006 Oct; 40(4):413-33. PubMed ID: 17205702 [TBL] [Abstract][Full Text] [Related]
28. Herpes Simplex Virus Type 2 Is More Difficult to Neutralize by Antibodies Than Herpes Simplex Virus Type 1. Silke Heilingloh C; Lull C; Kleiser E; Alt M; Schipper L; Witzke O; Trilling M; Eis-Hübinger AM; Dittmer U; Krawczyk A Vaccines (Basel); 2020 Aug; 8(3):. PubMed ID: 32867086 [TBL] [Abstract][Full Text] [Related]
31. A vaccine containing highly purified virus particles in adjuvant provides high level protection against genital infection and disease in guinea pigs challenged intravaginally with homologous and heterologous strains of herpes simplex virus type 2. Bernstein DI; Morello CS; Cardin RD; Bravo FJ; Kraynyak KA; Spector DH Vaccine; 2020 Jan; 38(1):79-89. PubMed ID: 31611098 [TBL] [Abstract][Full Text] [Related]
32. The challenges and opportunities for the development of a T-cell epitope-based herpes simplex vaccine. Kuo T; Wang C; Badakhshan T; Chilukuri S; BenMohamed L Vaccine; 2014 Nov; 32(50):6733-45. PubMed ID: 25446827 [TBL] [Abstract][Full Text] [Related]
33. Genital herpes in a sexually-transmitted infection clinic in Singapore: a 1-year retrospective study. Theng TS; Chan RK Ann Acad Med Singap; 2004 Mar; 33(2):200-3. PubMed ID: 15098634 [TBL] [Abstract][Full Text] [Related]
34. A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections. Chiuppesi F; Vannucci L; De Luca A; Lai M; Matteoli B; Freer G; Manservigi R; Ceccherini-Nelli L; Maggi F; Bendinelli M; Pistello M J Virol; 2012 Jun; 86(12):6563-74. PubMed ID: 22491465 [TBL] [Abstract][Full Text] [Related]
35. Multivalent DNA vaccine protects against genital herpes by T-cell immune induction in vaginal mucosa. Kim HC; Oh DS; Park JH; Kim HJ; Seo YB; Yoo HJ; Jang HS; Shin J; Kim CW; Kwon MS; Jin HT; Lee SK; Oh JE; Lee HK Antiviral Res; 2020 May; 177():104755. PubMed ID: 32112797 [TBL] [Abstract][Full Text] [Related]
36. Current thinking on genital herpes. Hofstetter AM; Rosenthal SL; Stanberry LR Curr Opin Infect Dis; 2014 Feb; 27(1):75-83. PubMed ID: 24335720 [TBL] [Abstract][Full Text] [Related]
37. The potential impact of a prophylactic herpes simplex vaccine. Rupp R; Bernstein DI Expert Opin Emerg Drugs; 2008 Mar; 13(1):41-52. PubMed ID: 18321147 [TBL] [Abstract][Full Text] [Related]